Operator
Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the CytomX Therapeutics First Quarter 2021 Financial Results Call. Please be advised that today s call is being recorded. I would now like to hand the conference over to your host for today, Chau Cheng, CytomX Vice President, Investor Relations and Corporate Communications. Please go ahead.
Chau Cheng
Vice President, Investor Relations and Corporate Communications
Thank you, Susan. Good afternoon, and thank you for joining us. With me today are Dr. Sean McCarthy, CytomX s President, Chief Executive Officer and Chairman; and Carlos Campoy, Chief Financial Officer. Earlier today, we issued a press release that includes a summary of our first quarter 2021 financial results and highlights the important progress we made during the quarter. We encourage everyone to read today s press release and the associated materials, which have been filed with the SEC. Additionally, the press release and the rec
Operator
Good afternoon, ladies and gentlemen, thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter and Full Year 2020 Financial Results Call. Please be advised that today s call is being recorded.
I would now like to hand the conference over to your host for today, Chau Cheng, CytomX s Vice President, Investor Relations and Corporate Communications. Please go ahead.
Chau Cheng
Vice President, Investor Relations and Corporate Communications
Thank you, Victor. Good afternoon, and thank you for joining us. With me today are Dr. Sean McCarthy, CytomX s President, Chief Executive Officer and Chairman; Dr. Amy Peterson; Chief Development Officer; and Carlos Campoy, Chief Financial Officer. Earlier today, we issued a press release that includes a summary of our fourth quarter and full year 2020 financial and highlights the important progress we made during the year. We encourage everyone to read today s press release and the associated materials, which have
CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
January 20, 2021 21:50 ET | Source: CytomX Therapeutics Inc. CytomX Therapeutics Inc. South San Francisco, California, UNITED STATES
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced the pricing of an underwritten public offering of 14,285,714 shares of its common stock at a price to the public of $7.00 per share, for gross proceeds of $100 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by CytomX. All shares are being offered by CytomX. In addition, CytomX has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 shares of its common stock at the public o
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage, oncology-focused biopharmaceutical .